Cargando…
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer
CD4(+)CD25(+)Foxp3(+) regulatory T cells (Treg) have emerged as a dominant T cell population inhibiting anti-tumor effector T cells. Initial strategies used for Treg-depletion (cyclophosphamide, anti-CD25 mAb…) also targeted activated T cells, as they share many phenotypic markers. Current, ameliora...
Autores principales: | Pere, Helene, Tanchot, Corinne, Bayry, Jagadeesh, Terme, Magali, Taieb, Julien, Badoual, Cecile, Adotevi, Olivier, Merillon, Nathalie, Marcheteau, Elie, Quillien, Ve´ronique, Banissi, Claire, Carpentier, Alain, Sandoval, Federico, Nizard, Mevyn, Quintin-Colonna, Françoise, Kroemer, Guido, Fridman, Wolf H., Zitvogel, Laurence, Oudard, Ste´phane, Tartour, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382865/ https://www.ncbi.nlm.nih.gov/pubmed/22737608 http://dx.doi.org/10.4161/onci.18852 |
Ejemplares similares
-
Modulation of Immunity by Antiangiogenic Molecules in Cancer
por: Terme, Magali, et al.
Publicado: (2012) -
VEGF-A modulates expression of inhibitory checkpoints on CD8(+) T cells in tumors
por: Voron, Thibault, et al.
Publicado: (2015) -
Immunotherapy of HPV-associated head and neck cancer: Critical parameters
por: Nizard, Mevyn, et al.
Publicado: (2013) -
Control of the Immune Response by Pro-Angiogenic Factors
por: Voron, Thibault, et al.
Publicado: (2014) -
Following up tumor-specific regulatory T cells in cancer patients
por: Zitvogel, Laurence, et al.
Publicado: (2013)